Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen on B cells durable remissions have been achieved in patients with B cell non-Hodgkin lymphoma and acute lymphoblastic...

Full description

Bibliographic Details
Main Authors: Nirav N. Shah, Theresa Maatman, Parameswaran Hari, Bryon Johnson
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Oncology
Subjects:
CAR-T
antigen escape
B-cell NHL
B-cell ALL
immunotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00146/full

Similar Items

Similar Items